PLRX Stock Risk & Deep Value Analysis
Pliant Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PLRX Stock
We analyzed Pliant Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PLRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is PLRX Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for PLRX?
- ⚠
Negative or inconclusive data from ALPINE Phase 2a study in PSC
- ⚠
Significant equity dilution to fund ongoing operations
- ⚠
Termination or delays in the Novartis partnership
- ⚠
Emergence of competitive therapies in PSC or other target indications
Unlock PLRX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Pliant Therapeutics Inc (PLRX) Do?
Market Cap
$100.68M
Sector
Healthcare
Industry
Biotechnology
Employees
171
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit Pliant Therapeutics Inc WebsiteIs PLRX Stock Undervalued?
Unlock the full AI analysis for PLRX
Get the complete DVR score, risk analysis, and more
Does PLRX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The moat's durability hinges entirely on the clinical success of the remaining pipeline assets (bexotegrast in PSC, PLRX-1001). While the underlying integrin platform is proprietary, its commercial value is directly tied to successful drug development.
Moat Erosion Risks
- •Clinical failures in ongoing trials reducing the value of the IP
- •Emergence of superior or more broadly effective competing therapies
- •Patent expiration over the long term
PLRX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive PLRX Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated late March / early April 2026)
- •Updates on ALPINE Phase 2a study enrollment and progress in PSC (Q2/Q3 2026)
Medium-Term (6-18 months)
- •Potential interim or full data readout from ALPINE Phase 2a study in PSC (Estimated Q4 2026 / H1 2027)
- •Progress updates on PLRX-1001 program with Novartis (e.g., Phase 1/2 initiation or data)
Long-Term (18+ months)
- •Initiation of Phase 3 trial for bexotegrast in PSC or other fibrotic indications
- •Expansion of proprietary integrin inhibitor platform to new therapeutic areas
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PLRX?
- ✓
Positive Phase 2a ALPINE data in PSC (efficacy and safety)
- ✓
Securing non-dilutive financing or new strategic partnerships
- ✓
Significant extension of cash runway
- ✓
Any signs of progress or data from the PLRX-1001 (Novartis) program
Bull Case Analysis
See what could go right with Premium
Compare PLRX to Similar Stocks
See how Pliant Therapeutics Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PLRX (Pliant Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
